IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway

IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway

Abstract Background Sorafenib is the standard targeted drug used to treat hepatocellular carcinoma (HCC), but the therapeutic response between individuals varies markedly. Recently, cytokine-based immunotherapy has been a topic of intense discussion in the fight against cancer. The aim of this study...

Full description

Bibliographic Details
Main Authors: Xiaoyan Ding, Wei Sun, Jinglong Chen
Format: Article
Language:English
Published: BMC 2018-11-01
Series:Cancer Cell International
Subjects:
IL-2
Sorafenib
Mitochondrial fission
Liver cancer
JNK-TAZ pathways
Online Access:http://link.springer.com/article/10.1186/s12935-018-0671-3

Similar Items

Similar Items